Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background: Evidence of antibody-mediated injury in the absence of donor-specific HLA antibodies (HLA-DSA) has recently emerged, suggesting a role of antibodies in targeting non-HLA antigens expressed on renal allograft tissue. However, the clinical significance of pre-transplant non-HLA antibodies remains unclear. We compared the histological and clinical impact of pre-transplant HLA-DSA and non-HLA antibodies, especially angiotensin II type I receptor (anti-AT1R) and MHC class I-related chain A (anti-MICA), in kidney transplant patients. Methods: Pre-transplant HLA-DSA, anti-AT1R, and anti-MICA were retrospectively examined in 359 kidney transplant patients to determine the effect of each antibody on allograft survival and clinical characteristics. Results: Pre-transplant HLA-DSA, anti-AT1R, and anti-MICA were detected in 37 (10.3%), 174 (48.5%), and 50 patients (13.9%), respectively. Post-transplant antibody-mediated rejection was associated with a pre-transplant HLA-DSA (+) status only. The development of microvascular inflammation (MVI) was associated with pre-transplant HLA-DSA (P=0.001) and anti-AT1R (P=0.036). Anti-AT1R (+) patients had significantly lower allograft survival compared with anti-AT1R (−) patients (P=0.042). Only pre-transplant anti-AT1R positivity was an independent risk factor for allograft failure (hazard ratio 4.824, confidence interval 1.017–24.888; P=0.038). MVI was the most common histological feature of allograft failure in patients with pre-transplant anti-AT1R. Conclusions: Pre-transplant anti-AT1R is an important risk factor for allograft failure, which may be mediated by MVI induction in the allograft tissue.
Abstract
Background: Evidence of antibody-mediated injury in the absence of donor-specific HLA antibodies (HLA-DSA) has recently emerged, suggesting a role of antibodies in targeting non-HLA antigens expressed on renal allograft tissue. However, the clinical significance of pre-transplant non-HLA antibodies remains unclear. We compared the histological and clinical impact of pre-transplant HLA-DSA and non-HLA antibodies, especially angiotensin II type I receptor (anti-AT1R) and MHC class I-related chain A (anti-MICA), in kidney transplant patients. Methods: Pre-transplant HLA-DSA, anti-AT1R, and anti-MICA were retrospectively examined in 359 kidney transplant patients to determine the effect of each antibody on allograft survival and clinical characteristics. Results: Pre-transplant HLA-DSA, anti-AT1R, and anti-MICA were detected in 37 (10.3%), 174 (48.5%), and 50 patients (13.9%), respectively. Post-transplant antibody-mediated rejection was associated with a pre-transplant HLA-DSA (+) status only. The development of microvascular inflammation (MVI) was associated with pre-transplant HLA-DSA (P=0.001) and anti-AT1R (P=0.036). Anti-AT1R (+) patients had significantly lower allograft survival compared with anti-AT1R (−) patients (P=0.042). Only pre-transplant anti-AT1R positivity was an independent risk factor for allograft failure (hazard ratio 4.824, confidence interval 1.017–24.888; P=0.038). MVI was the most common histological feature of allograft failure in patients with pre-transplant anti-AT1R. Conclusions: Pre-transplant anti-AT1R is an important risk factor for allograft failure, which may be mediated by MVI induction in the allograft tissue.
참고문헌 (34)
- Terasaki PI, "Predicting kidney graft failure by HLA antibodies: a prospective trial", Am J Transplant, 4, pp.438~443 (2004)[DOI]
- Loupy A, "Complement-binding anti-HLA antibodies and kidney-allograft survival", N Engl J Med, 369, pp.1215~1226 (2013)[DOI]
- Wiebe C, "Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant", Am J Transplant, 12, pp.1157~1167 (2012)[DOI]
- Opelz G, "Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies", Lancet, 365, pp.1570~1576 (2005)[DOI]
- Tait BD, "Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation", Transplantation, 95, pp.19~47 (2013)[DOI]
- Dragun D, "Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection", N Engl J Med, 352, pp.558~569 (2005)[DOI]
- Reinsmoen NL, "Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients", Transplantation, 90, pp.1473~1477 (2010)[DOI]
- Luo L, "The role of HIF-1 in up-regulating MICA expression on human renal proximal tubular epithelial cells during hypoxia", reoxygenation, 2010, pp.11, 91~
- Giral M, "Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss", Am J Transplant, 13, pp.2567~2576 (2013)[DOI]
- Sanchez-Zapardiel E, "Early renal graft function deterioration in recipients with preformed anti-MICA antibodies: partial contribution of complement-dependent cytotoxicity", Nephrol Dial Transplant, 31, pp.150~160 (2016)[DOI]
- Taniguchi M, "Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies", Am J Transplant, 13, pp.2577~2589 (2013)[DOI]
- Lee J, "Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation", Transplant Proc, 47, pp.649~652 (2015)[DOI]
- Zou Y, "Antibodies against MICA antigens and kidney-transplant rejection", N Engl J Med, 357, pp.1293~1300 (2007)[DOI]
- Philogene MC, "Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies", Transplantation, 101, pp.608~615 (2017)[DOI]
- Chung BH, "Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy", Transpl Int, 27, pp.49~59 (2014)[DOI]
- Fuss A, "C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies", Nephrology (Carlton), 20, pp.467~473 (2015)[DOI]
- Chung BH, "Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation", Ren Fail, 33, pp.150~158 (2011)[DOI]
- Haas M, "Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions", Am J Transplant, 14, pp.272~283 (2014)[DOI]
- Banasik M, "The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes", Transpl Int, 27, pp.1029~1038 (2014)[DOI]
- Lee J, "The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation", Nephrol Dial Transplant, 32, pp.1244~1250 (2017)
- Sanchez-Zapardiel E, "Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period", Transplantation, 96, pp.70~78 (2013)[DOI]
- Caro-Oleas JL, "Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation", Nephrol Dial Transplant, 27, pp.1231~1238 (2012)[DOI]
- Lefaucheur C, "Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation", J Am Soc Nephrol, 21, pp.1398~1406 (2010)[DOI]
- Harrison-Bernard LM, "Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody", Am J Physiol, 273, pp.F170~F177 (1997)
- Kill A, "Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis", Arthritis Res Ther, 16, pp.R29~ (2014)[DOI]
- Win TS, "Humoral autoimmunity and transplant vasculopathy: when allo is not enough", Transplantation, 90, pp.113~120 (2010)
- Stegall MD, "The role of complement in antibody-mediated rejection in kidney transplantation", Nat Rev Nephrol, 8, pp.670~678 (2012)[DOI]
- Cuevas E, "Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies", Nephrol Dial Transplant, 31, pp.1738~1745 (2016)[DOI]
- Chung BH, "Impact of ABO incompatibility on the development of acute antibody-mediated rejection in kidney transplant recipients presensitized to HLA", PLoS One, 10, pp.e0123638~ (2015)[DOI]
- 김명규, "Does the timing of acute rejection matter with the graft outcome in kidney transplantation?", Kidney Research and Clinical Practice, 34(3), pp.123~124 (2015), 대한신장학회
- 구은희, "The impact of early and late acute rejection on graft survival in renal transplantation", Kidney Research and Clinical Practice, 34(3), pp.160~164 (2015), 대한신장학회
- Luo L, "Role of MICA antibodies in solid organ transplantation", Clin Transplant, 28, pp.152~160 (2014)[DOI]
- European Renal Best Practice Transplantation Guideline Development G, "ERBP guideline on the management and evaluation of the kidney donor and recipient", Nephrol Dial Transplant, 28(S2), pp.ii1~ii71 (2013)[DOI]
- 이혜영, "Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection", Annals of Laboratory Medicine, 35(3), pp.314~320 (2015), 대한진단검사의학회